Cortés-Hernández Luis Enrique, Eslami-S Zahra, Attina Aurore, Batista Silvia, Cayrefourcq Laure, Vialeret Jérôme, Di Vizio Dolores, Hirtz Christophe, Costa-Silva Bruno, Alix-Panabières Catherine
Laboratory of Rare Human Circulating Cells, University Medical Center of Montpellier, Montpellier, France.
CREEC, MIVEGEC, University of Montpellier, CNRS, IRD, Montpellier, France.
J Exp Clin Cancer Res. 2025 Mar 22;44(1):102. doi: 10.1186/s13046-025-03360-4.
Circulating tumor cells (CTCs) are pivotal in cancer progression, and in vitro CTC models are crucial for understanding their biological mechanisms. This study focused on the characterization of extracellular vesicles (EVs) from CTC lines derived from a patient with metastatic colorectal cancer (mCRC) at different stages of progression who progressed despite therapy (thus mirroring the clonal evolution of cancer).
Morphological and size analyses revealed variations among EVs derived from different CTC lines. Compared with the Vesiclepedia database, proteomic profiling of these EVs revealed enrichment of proteins related to stemness, endosomal biogenesis, and mCRC prognosis. Integrin family proteins were significantly enriched in EVs from CTC lines derived after therapy failure. The role of these EVs in cancer progression was analyzed by assessing their in vivo distribution, particularly in the liver, lungs, kidneys, and bones. EVs accumulate significantly in the liver, followed by the lungs, kidneys and femurs.
This study is a pioneering effort in highlighting therapy progression-associated changes in EVs from mCRC patients via an in vitro CTC model. The results offer insights into the role of metastasis initiator CTC-derived EVs in cancer spread, suggesting their utility for studying cancer tissue distribution mechanisms. However, these findings must be confirmed and extended to patients with mCRC. This work underscores the potential of CTC-derived EVs as tools for understanding cancer dissemination.
循环肿瘤细胞(CTC)在癌症进展中起关键作用,体外CTC模型对于理解其生物学机制至关重要。本研究聚焦于来自一名转移性结直肠癌(mCRC)患者不同进展阶段的CTC系来源的细胞外囊泡(EV)的特征,该患者尽管接受了治疗仍出现进展(从而反映癌症的克隆进化)。
形态学和大小分析揭示了来自不同CTC系的EV之间的差异。与Vesiclepedia数据库相比,这些EV的蛋白质组学分析显示与干性、内体生物发生和mCRC预后相关的蛋白质富集。整合素家族蛋白在治疗失败后衍生的CTC系来源的EV中显著富集。通过评估它们在体内的分布,特别是在肝脏、肺、肾脏和骨骼中的分布,分析了这些EV在癌症进展中的作用。EV在肝脏中显著积聚,其次是肺、肾脏和股骨。
本研究是一项开创性的工作,通过体外CTC模型突出了mCRC患者EV中与治疗进展相关的变化。结果为转移起始CTC衍生的EV在癌症扩散中的作用提供了见解,表明它们在研究癌症组织分布机制方面的实用性。然而,这些发现必须在mCRC患者中得到证实和扩展。这项工作强调了CTC衍生的EV作为理解癌症播散工具的潜力。